October 12, 2020 -- Vaccine biotechnology firm AuraVax Therapeutics has entered into an exclusive licensing option agreement with the University of Houston for a unique intranasal vaccine technology.
The agreement allows AuraVax to exclusively license patents utilizing intellectual property related to the novel vaccine platform. The company intends to advance the technology to create vaccines that address multiple respiratory viruses, including SARS-CoV-2.
AuraVax is based out of Houston and was created by a professor at the University of Houston. The company's first goal is to create a more effective way to vaccinate against COVID-19.